Type 1 plasminogen activator inhibitor
(PAI-1) in clear cell renal cell carcinoma (CCRCC) and its impact on angiogenesis, progression and patient survival after radical nephrectomy.
Keeton et al., "Altered expression of plasminogen activator inhibitor
type 1 in placentas from pregnant women with preeclampsia and/or intrauterine fetal growth retardation," Blood, vol.
Wiman, "Plasminogen activator inhibitor
1 (PAI-1) in plasma: its role in thrombotic disease," Thrombosis and Haemostasis, vol.
The plasma concentration of fibrinogen, tissue-type plasminogen activator (tPA) and plasminogen activator inhibitor
(PAI-1) were measured by standard sandwich ELISA technique using commercial kits (Diagnostica STAGO, R.C.S.
Urokinase plasminogen activator (uPA) system, comprising of uPA, its receptor uPAR and inhibitor, type 1 plasminogen activator inhibitor
(PAI-1), plays a vital role in various biological processes involving extracellular proteolysis, fibrinolysis, cell migration and proliferation.
Loskutoff, "Kinetic analysis of the interactions between plasminogen activator inhibitor
1 and both urokinase and tissue plasminogen activator," Archives of Biochemistry and Biophysics, vol.
The Example of Urokinase-Type Plasminogen Activator and Its Inhibitor Plasminogen Activator Inhibitor
For example, testosterone treatment is reported to reduce serum levels of the pro-inflammatory cytokines interleukin (IL)-1beta and tumor necrosis factor (TNF)-alpha, and to increase levels of the anti-inflammatory cytokine IL-10; to reduce vascular cell adhesion molecule (VCAM)-1 expression in aortic endothelial cells; to promote vascular smooth muscle and endothelial cell proliferation; to induce vasodilatation and to improve vascular reactivity, to reduce serum levels of the pro-thrombotic factors plasminogen activator inhibitor
(PAI)-1 and fibrinogen; to reduce low-density lipoprotein-cholesterol (LDL-C); to improve insulin sensitivity; and to reduce body mass index and visceral fat mass.
High lipid levels were the only risk factor for Ml in our patient and progesterone use might have induced an increase in plasminogen activator inhibitor
levels and vasospasm promoting thrombus formation.
Insulin resistance is known to dysregulate the fibrinolytic system, such as the elevation of plasminogen activator inhibitor
1 and other endogenous inhibitors of fibrinolysis, and to create a proinflammatory state.
These inflammatory markers included interleukin (IL)-6, IL-8, and IL-10, tumor necrosis factor-[alpha], epidermal growth factor, vascular endothelial growth factor, and plasminogen activator inhibitor
, as well as C-reactive protein.